• Molecular NameAzatadine
  • SynonymAzatadina [INN-Spanish]; Azatadine Maleate; Azatadinum [INN-Latin]; Azatidine
  • Weight290.41
  • Drugbank_IDDB00719
  • ACS_NO3964-81-6
  • Show 2D model
  • LogP (experiment)3.6
  • LogP (predicted, AB/LogP v2.0)3.79
  • pkaN/A
  • LogD (pH=7, predicted)2.2
  • Solubility (experiment)Soluble
  • LogS (predicted, ACD/Labs)(ph=7)-1.77
  • LogSw (predicted, AB/LogsW2.0)0.02
  • Sw (mg/ml) (predicted, ACD/Labs)0.09
  • No.of HBond Donors0
  • No.of HBond Acceptors2
  • No.of Rotatable Bonds0
  • TPSA16.13
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyAn antihistamine.
  • Absorption_value90.0
  • Absorption (description)Well absorbed after oral administration.
  • Caco_2N/A
  • BioavailabilityN/A
  • Protein bindingN/A
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmThe main paths of azatadine metabolism in humans are aliphatic and aromatic hydroxylation and N-demethylation.
  • Half lifeN/A
  • ExcretionN/A
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityThe oral LD50 in mature rats and mice was greater than 1700 mg/kg and 600 mg/kg, respectively. Symptoms of overdose include clumsiness or unsteadiness, seizures, severe drowsiness, flushing or redness of face, hallucinations, muscle spasms (especially of neck and back), restlessness, shortness of breath, shuffling walk, tic-like (jerky) movements of head and face, trembling and shaking of hands, and insomnia.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A